Abstract
Background
Inflammatory bowel disease (IBD) is a chronic inflammatory disease, which involves the gut and comprises of Crohn’s disease (CD) and ulcerative colitis (UC). Immune cells, including natural killer (NK) cells, play an important role in the pathogenesis of the disease. Killer immunoglobulin-like receptors (KIRs) are NK cell surface receptors, which ligate to the class I major histocompatibility complex (MHC) and have inhibitory or activating effects on the NK cells. The aim of this study was to perform a meta-analysis of the six studies evaluating the association in the polymorphisms of these KIR genes and the IBD risk (4 UC and 5 CD studies).
Methods
A systematic search was conducted in the electronic databases to find all the studies on the KIR gene polymorphism in IBD patients prior to December 2017. The odds ratio (OR) and 95% confidence interval (CI) were used to find any association between KIR gene polymorphisms and the IBD risk.
Results
Following extraction of the data from the studies, which were screened by inclusion and exclusion criteria, collectively 432 patients and 886 controls for UC and 1677 patients and 1308 controls for CD were included in the meta-analysis. The statistical evaluation demonstrated positive associations between 2DL5 (OR=1.31, 95% CI=1.01–1.69) and 2DS1 (OR=1.33, 95% CI=1.01–1.76) members of KIR genes and UC risk, as well a negative association between 2DS3 gene and CD risk was detected (OR=0.74, 95% CI=0.60–0.90).
Conclusions
There are positive associations between 2DL5 and 2DS1 members of KIR genes and UC risk and a negative association between 2DS3 and CD risk.
Similar content being viewed by others
References
Hansen JJ, Sartor RB. Therapeutic manipulation of the microbiome in IBD: current results and future approaches. Curr Treat Opt Gastroenterol. 2015;13:105–20.
Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–7.
Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease, seminars in immunopathology, vol. 37. Berlin: Springer; 2015.
Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744–52.
Ford AC, Moayyedi P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, et al. Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care. Am J Gastroenterol. 2015;110:716–24.
De Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016;13:13–27.
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633–40.
Steel A, Mela C, Lindsay J, Gazzard B, Goodier M. Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther. 2011;33:115–26.
Takayama T, Kamada N, Chinen H, Okamoto S, Kitazume MT, Chang J, et al. Imbalance of NKp44+ NKp46− and NKp44− NKp46+ natural killer cells in the intestinal mucosa of patients with Crohn’s disease. Gastroenterology. 2010;139:882–92.e3.
Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JK, et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature. 2009;457:722–5.
Trowsdale J. Genetic and functional relationships between MHC and NK receptor genes. Immunity. 2001;15:363–74.
Falco M, Moretta L, Moretta A, Bottino C. KIR and KIR ligand polymorphism: a new area for clinical applications? HLA. 2013;82:363–73.
López-Hernández R, Campillo JA, Legaz I, Valdés M, Salama H, Boix F, et al. Killer immunoglobulin-like receptor (KIR) repertoire analysis in a Caucasian Spanish population with inflammatory bowel diseases. Microbiol Immunol. 2016;60:787–92.
Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11:193.
Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315:629–34.
Jones D, Edgar R, Ahmad T, Cummings J, Jewell D, Trowsdale J, et al. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun. 2006;7:576–82.
Wilson TJ, Jobim M, Jobim LF, Portela P, Salim PH, Rosito MA, et al. Study of killer immunoglobulin-like receptor genes and human leukocyte antigens class I ligands in a Caucasian Brazilian population with Crohn’s disease and ulcerative colitis. Hum Immunol. 2010;71:293–7.
Zhang H, Liu S, Liu Z, Li J. Expression of iKIR-HLA-Cw in patients with inflammatory bowel disease. Life Sci J. 2008;5:17–22.
Hollenbach JA, Ladner MB, Saeteurn K, Taylor KD, Mei L, Haritunians T, et al. Susceptibility to Crohn’s disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics. 2009;61:663.
Díaz-Peña R, Vidal-Castiñeira JR, Moro-García MA, Alonso-Arias R, Castro-Santos P. Significant association of the KIR2DL3/HLA-C1 genotype with susceptibility to Crohn’s disease. Hum Immunol. 2016;77:104–9.
Körner C, Altfeld M. Role of KIR3DS1 in human diseases. Front Immunol. 2012;3:326.
Stewart CA, Laugier-Anfossi F, Vély F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide–MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA. 2005;102:13224–9.
Erer B, Takeuchi M, Ustek D, Tugal-Tutkun I, Seyahi E, Özyazgan Y, et al. Evaluation of KIR3DL1/KIR3DS1 polymorphism in Behçet’s disease. Genes Immun. 2016;17:396.
Li X, Xia Q, Fan D, Cai G, Yang X, Wang L, et al. Association between KIR gene polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis. Hum Immunol. 2015;76:565–70.
García-León JA, Pinto-Medel MJ, García-Trujillo L, López-Gómez C, Oliver-Martos B, Prat-Arrojo I, et al. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol Immunol. 2011;48:1896–902.
Díaz-Peña R, Vidal-Castiñeira JR, Mulero J, Sánchez A, Queiro R, López-Larrea C. Activating killer immunoglobulin-like receptors genes are associated with increased susceptibility to ankylosing spondylitis. Clin Exp Immunol. 2015;180:201–6.
Suzuki Y, Hamamoto Y, Ogasawara Y, Ishikawa K, Yoshikawa Y, Sasazuki T, et al. Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J Investig Dermatol. 2004;122:1133–6.
Traherne JA, Jiang W, Valdes AM, Hollenbach JA, Jayaraman J, Lane JA, et al. KIR haplotypes are associated with late-onset type 1 diabetes in European–American families. Genes Immun. 2016;17:8–12.
Dastmalchi R, Farazmand A, Noshad S, Mozafari M, Mahmoudi M, Esteghamati A, et al. Polymorphism of killer cell immunoglobulin-like receptors (KIR) and their HLA ligands in Graves’ disease. Mol Biol Rep. 2014;41:5367–74.
Mahmoudi M, Fallahian F, Sobhani S, Ghoroghi S, Jamshidi A, Poursani S, et al. Analysis of killer cell immunoglobulin-like receptors (KIRs) and their HLA ligand genes polymorphisms in Iranian patients with systemic sclerosis. Clin Rheumatol. 2017;36:853–62.
Bashirova AA, Martin MP, McVicar DW, Carrington M. The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet. 2006;7:277–300.
Yusa S, Catina T, Campbell K. KIR2DL5 can inhibit human NK cell activation via recruitment of Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2). J Immunol (Baltimore: 1950). 2004;172:7385–92.
VandenBussche C, Mulrooney T, Frazier W, Dakshanamurthy S, Hurley C. Dramatically reduced surface expression of NK cell receptor KIR2DS3 is attributed to multiple residues throughout the molecule. Genes Immun. 2009;10:162–74.
Acknowledgements
This study was supported by a Grant from Tehran University of Medical Sciences (Grant No. 92-02-41-23195).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Responsible Editor: John Di Battista.
Rights and permissions
About this article
Cite this article
Fathollahi, A., Aslani, S., Mostafaei, S. et al. The role of killer-cell immunoglobulin-like receptor (KIR) genes in susceptibility to inflammatory bowel disease: systematic review and meta-analysis. Inflamm. Res. 67, 727–736 (2018). https://doi.org/10.1007/s00011-018-1162-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-018-1162-7